BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 21546514)

  • 1. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
    Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
    Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neovascular age-related macular degeneration.
    Veritti D; Sarao V; Lanzetta P
    Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK; Moon HJ
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
    Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C; Semeraro F; dell'Omo R; Romano MR; Russo A; Aceto F; Mastropasqua R; Porcellini A
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept in wet AMD: specific role and optimal use.
    Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
    Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial.
    Lai TY; Liu DT; Chan KP; Luk FO; Pang CP; Lam DS
    Retina; 2009 Oct; 29(9):1218-26. PubMed ID: 19934816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
    Wu L; Arevalo JF; Hernandez-Bogantes E; Regatieri CV; Roca JA; Farah ME
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
    Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography.
    Nagiel A; Freund KB; Spaide RF; Munch IC; Larsen M; Sarraf D
    Am J Ophthalmol; 2013 Nov; 156(5):981-988.e2. PubMed ID: 23972309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical coherence tomography angiography of type 3 neovascularisation in age-related macular degeneration after antiangiogenic therapy.
    Phasukkijwatana N; Tan ACS; Chen X; Freund KB; Sarraf D
    Br J Ophthalmol; 2017 May; 101(5):597-602. PubMed ID: 27503396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in pharmacotherapy for wet age-related macular degeneration.
    Santarelli M; Diplotti L; Samassa F; Veritti D; Kuppermann BD; Lanzetta P
    Expert Opin Pharmacother; 2015; 16(12):1769-81. PubMed ID: 26165696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.